Regeneron Pharmaceuticals Inc. recently unveiled its latest corporate presentation, highlighting significant advancements in their R&D pipeline and financial performance for Q2 2025. The company reported total revenues of $3.68 billion and a non-GAAP EPS of $12.89 for the second quarter. Notable R&D advancements include extended dosing intervals for certain treatments and approvals for new uses of existing drugs. Regeneron's oncology strategy focuses on leveraging the immune system to combat cancer through five classes of immunomodulatory agents, with several demonstrating potentially best-in-class clinical efficacy. The presentation also underscored Regeneron's commitment to innovation with their Genetic Medicines Program, which customizes genetics technology for therapeutic applications. You can access the full presentation through the link below.